Bioline RX Ltd (BLRX) Given Consensus Recommendation of “Hold” by Brokerages
Shares of Bioline RX Ltd (NASDAQ:BLRX) have been given a consensus rating of “Hold” by the seven ratings firms that are presently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell rating and five have given a buy rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $3.20.
Several equities research analysts have recently issued reports on the company. Oppenheimer assumed coverage on Bioline RX in a research report on Thursday, December 21st. They issued a “buy” rating and a $3.00 price target on the stock. HC Wainwright set a $4.00 price target on Bioline RX and gave the company a “buy” rating in a research report on Thursday, December 21st. Maxim Group set a $3.00 price target on Bioline RX and gave the company a “buy” rating in a research report on Monday, December 4th. ValuEngine raised Bioline RX from a “strong sell” rating to a “sell” rating in a research report on Thursday, November 30th. Finally, Zacks Investment Research downgraded Bioline RX from a “hold” rating to a “sell” rating in a research report on Monday, November 27th.
Shares of Bioline RX (NASDAQ:BLRX) traded down $0.05 during trading hours on Monday, hitting $1.10. The stock had a trading volume of 1,060,000 shares, compared to its average volume of 651,342. The firm has a market capitalization of $121.08, a P/E ratio of -3.48 and a beta of 0.88. Bioline RX has a 12 month low of $0.80 and a 12 month high of $1.38.
Bioline RX Company Profile
BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.
Receive News & Ratings for Bioline RX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioline RX and related companies with Analyst Ratings Network's FREE daily email newsletter.